Results 61 to 70 of about 10,851,050 (358)

Inhaled corticosteroids versus long-acting beta -agonists for chronic obstructive pulmonary disease (Review). [PDF]

, 2011
Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler.
Agarwal, Anderson, Appleton, Barnes, Borgstrom, Borgstrom, Boyd, Burge, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverly, Campbell, Campell, Cazzola, Cazzola, Celli, Celli, Celli, Celli, Corhay, Dahl, Della Cioppa, Egede, Ferguson, Ferguson, Gosman, Greefhorst, Halpin, Halpin, Halpin, Hanania, Hanania, Hanania, Higgins, Horstman, Hunjan, Hunjan, Hunjan, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Keene, Korsgaard, Kristufek, Lange, Lofdahl, Lofdahl, Lofdahl, Lofdahl, Lyseng-Williamson, Mahler, Mahler, Mahler, McGarvey, Milanowski, Nannini, Nannini, Nannini Luis, Nitschmann, Pauwels, Pauwels, Reynolds, Rodrigo, Rodrigo, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Szafranski, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Yang   +105 more
core   +2 more sources

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges, Kelly A. Duffy, Sara McDonough, Evelyn Kurpiewski, R. Jennifer Randall, Allison Barz Leahy, Haley M. Newman, Joyce P. Lee, Stephen P. Hunger, Anne F. Reilly, David T. Teachey, Susan R. Rheingold, Daniel J. Zheng   +12 more
wiley   +1 more source

Nanoparticle-Assisted Sonosensitizers and Their Biomedical Applications

International Journal of Nanomedicine, 2021
Pengxuan Zhao,1 Youbin Deng,1 Guangya Xiang,2 Yani Liu1 1Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2School of Pharmacy, Tongji ...
Zhao P, Deng Y, Xiang G, Liu Y
doaj  

Modern Principles of Treatment of Uncontrolled Hypertension

Рациональная фармакотерапия в кардиологии, 2019
Despite the current possibilities of using different classes of antihypertensive drugs that effectively reduce blood pressure and significantly improve the long-term prognosis of patients, the problem of uncontrolled arterial hypertension has not lost ...
V. I. Podzolkov, A. I Tarzimanova, Z. O. Georgadze   +2 more
doaj   +1 more source

Nanoparticle-Based Combination Therapy for Melanoma

Frontiers in Oncology, 2022
Melanoma is a cutaneous carcinoma, and its incidence is rapidly increasing with every year. The treatment options for melanoma have been comprehensively studied.
Hongbo Chen, Kai Hou, Jing Yu, Le Wang, Xue Chen   +4 more
doaj   +1 more source

Optimized Treatment Schedules for Chronic Myeloid Leukemia

, 2016
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David, Foo, Jasmine, He, Qie, Leder, Kevin, Zhu, Junfeng   +4 more
core   +3 more sources

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment [PDF]

, 2010
Background Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a ...
de Knegt, Robert J, Desombere, Isabelle, Haagmans, Bart, Hansen, Bettina, Janssen, Harry LA, Leroux-Roels, Geert, Orlent, Hans, Schalm, Solko W, Van Vlierberghe, Hans   +8 more
core   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Progress in the Application of Nanomaterials in Tumor Treatment

Biomedicines
Cancer continues to pose a major global health burden, with conventional therapeutic modalities such as surgical resection, chemotherapy, radiotherapy, and immunotherapy often hindered by limited tumor specificity, substantial systemic toxicity, and the ...
Xingyu He, Lilin Wang, Tongtong Zhang, Tianqi Lu   +3 more
doaj   +1 more source

Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses

Nature Communications, 2017
Herein, an intelligent biodegradable hollow manganese dioxide (H-MnO2) nano-platform is developed for not only tumor microenvironment (TME)-specific imaging and on-demand drug release, but also modulation of hypoxic TME to enhance cancer therapy ...
Guangbao Yang, Ligeng Xu, Y. Chao, Jun Xu, Xiaoqi Sun, Yifan Wu, Rui Peng, Zhuang Liu   +7 more
semanticscholar   +1 more source